Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Has Consensus Target Price of $5.70 According to Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.70.

A number of research firms have recently weighed in on LXRX. Wall Street Zen lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings raised Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $8.00 price objective for the company. Finally, Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.88 on Monday. The stock has a market cap of $834.30 million, a PE ratio of -12.50 and a beta of 1.02. The company’s fifty day moving average is $2.22 and its 200 day moving average is $2.05. Lexicon Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $2.68. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 37.53% and a negative net margin of 147.38%.The business had revenue of $0.69 million during the quarter, compared to the consensus estimate of $3.99 million. Research analysts anticipate that Lexicon Pharmaceuticals will post -0.17 earnings per share for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of LXRX. WINTON GROUP Ltd boosted its holdings in shares of Lexicon Pharmaceuticals by 69.4% during the second quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 17,700 shares during the period. Squarepoint Ops LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $28,000. AXQ Capital LP raised its position in Lexicon Pharmaceuticals by 126.9% during the 2nd quarter. AXQ Capital LP now owns 45,727 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 25,577 shares during the last quarter. Wellington Management Group LLP bought a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $431,000. Finally, Bank of New York Mellon Corp purchased a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $1,365,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company that discovers and develops medicines for human disease. Founded in 1995 and headquartered in The Woodlands, Texas, the company uses its drug-discovery platform and expertise in biology to identify potential treatments for conditions with significant unmet medical needs.

Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral medicine used to treat carcinoid syndrome diarrhea in adults whose symptoms are not adequately controlled by somatostatin analog therapy.